Help us make Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this resource center more useful to clinicians.

Purpose The pharmacology, clinical efficacy, safety, dosage and administration, and place in therapy of fidaxomicin for the treatment of Clostridium difficile infection (CDI) are reviewed.

These studies have found that gut astrocytes are important regulators of mucosal barrier function and inflammation in inflammatory bowel disease, necrotizing enterocolitis and Clostridium difficile ...

NICE have found that the evidence supporting FMT for recurrent Clostridium difficile infection is sufficient for the procedure to be carried out. However, it is only considered when patients have ...